Navigation Links
Sweden to Receive Scandinavia's First TomoTherapy System : Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments
Date:7/31/2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has extended its reach in Europe with the first TomoTherapy HiArt treatment system set to be installed in Scandinavia, at Lund University Hospital in Sweden.

MADISON, Wis. (Business Wire EON) July 31, 2008 -- Jef Van Dam, general manager of TomoTherapyEMEA, said, "TomoTherapy is extremely pleased to partner with Lund University Hospital. This marks our entry into the Swedish market with a prestigious institution that pioneered the use of many technological advances in Scandinavia andEurope. We look forward to delivering the advanced HiArt system to continue that tradition."

Lund University Hospital conducted an extensive investigation of all commercially available intensity-modulated radiation therapy (IMRT) systems, including arc-based options on conventional platforms, before making the decision to purchase the TomoTherapy HiArt system.

Charlott Wictor, strategic purchaser of medical equipment for the Skane region in Sweden, championed TomoTherapy and helped the purchase become reality: "This was a great team effort working with the Lund medical and physics experts to bring this advanced technology to our Swedish patients. TomoTherapy was clearly the best choice from both a high technology and economic standpoint."

Jacob Engellau, M.D., Ph.D., head of radiation oncology at Lund University Hospital, believes TomoTherapy will have a great impact on patient treatments. "As a large center treating 2500 new patients yearly, we are dependent on high up-time and clinical reliability. The established and clinically well-implemented TomoTherapy HiArt was the only system that could meet the demands of our clinic."

Tommy Kns, Ph.D., associate professor and head of radiation physics at Lund University Hospital, was also an important decision maker in the process. "We think TomoTherapy is the most advanced image-guided system for radiotherapy with an integrated functionality for imaging and localisation of the target volume. It also produces the most advantageous dose distributions for IMRT," according to Kns.

Added Engellau, "With the HiArt system, we see obvious clinical advantages for treating complex radiation target volumes, multiple targets and targets requiring a high radiation dose with close proximity to healthy organs. Conventional 3D conformal radiation or IMRT can treat some but not all of these case types. If the cases can be attempted, we believe the results would be less conformal, less accurate and with much longer treatment times than with TomoTherapy."

While TomoTherapy will be used to treat a wide array of cancers, the clinical experts at Lund plan to focus on anal, rectal, cervical, stomach and esophageal cancers. They will also be using the HiArt system for stereotactic radiosurgery treatments and see greater possibilities for clinical trials involving simultaneously integrated boost (SIB) with or without dose escalation.

Lund University Hospital plans to install the TomoTherapy HiArt system later this year.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy HiArt treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The HiArt treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future events, expectations and other similar matters, including but not limited to statements using the terms "look forward to" or "will" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

2008 TomoTherapy Incorporated. All rights reserved.TomoTherapy, the TomoTherapy logo and HiArt are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Read the full story at http://www.prweb.com/releases/tomotherapy/lund_university/prweb1167744.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
2. The Feinstein to collaborate with Swedens Karolinska Institute
3. Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
7. Go Healthy Receives Letter of Recognition From the Texas Chiropractic Association
8. Eagle Ventures Subsidiary Hydrate2O Receives 2008 Top Gear of the Year Award From ShapeYou.com
9. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
10. French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia
11. Pandemic research receives $1.6M funding boost
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Sweden to Receive Scandinavia's First TomoTherapy System :  Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments 
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... ... ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is now ... without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. Horeb, ... receive early treatment, they may achieve straight teeth with less treatment in their teenage ...
(Date:3/29/2017)... Md., and MINNETONKA, Minn. (PRWEB) , ... March ... ... the development of medical office buildings (MOBs) and other outpatient facilities, and who ... project to look exclusively at those questions, Revista and Healthcare Real Estate Insights ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
(Date:3/29/2017)... ... , ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: ... recording of the webinar will also be made available following its live presentation. The ... are still popular targets for healthcare investors. This highly fragmented sector bounced back in ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... AMSTERDAM , March 29, 2017   ... global leader in health technology, and PathAI, a ... are collaborating with the aim to develop solutions ... diagnosis of cancer and other diseases. The partnership ... pathology, enabling this form of artificial intelligence to ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology: